# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

> **NCT02867735** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Macular Edema
- Diabetic Macular Edema
- Neovascular Age-related Macular Degeneration
- Retinal Vein Occlusions

## Interventions

- **DRUG:** LKA651
- **OTHER:** Sham Comparator

## Key facts

- **NCT ID:** NCT02867735
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-21
- **Primary completion:** 2018-02-15
- **Final completion:** 2018-02-15
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02867735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02867735, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02867735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*